All In Biotech

NDA 021879 · Otsuka America Pharm

Nuedexta

Dextromethorphan Hydrobromide, Quinidine Sulfate · Oral

Priority review

Last checked: Nov 19, 2026Latest source record: Jun 11, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Oct 29, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

206

29 Phase 3, 17 recruiting

FAERS reports

3,631

1,230 serious, 282 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 22, 2026.

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. NUEDEXTA is a combination product containing dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 agonist) and quinidine sulfate (a CYP450 2D6 inhibitor) indicated for the treatment of pseudobulbar affect (PBA). ( 1 )

Mechanism: Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. Quinidine increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NUEDEXTA · DEXTROMETHORPHAN HYDROBROMIDE 20MG; QUINIDINE SULFATE 10MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dextromethorphan Hydrobromide" as an intervention, any sponsor and status, largest first.

All 206 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fall208
  • off label use208
  • product use in unapproved indication195
  • death192
  • drug ineffective192
  • dizziness169
  • therapy interrupted161
  • fatigue145
  • diarrhoea135
  • nausea111
  • somnolence104
  • dysphagia102

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201116
201233
201338
201473
2015559
2016518
2017414
2018368
2019331
2020244
2021190
2022122
2023212
2024264
2025201
202648

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nuedexta (Dextromethorphan HBr/Quinidine)

2024 spending

$173M

Beneficiaries

15,788

158,337 claims

Per beneficiary

$10,955

$26.85 per unit

View as table
YearSpending
2020$212,633,559
2021$187,531,133
2022$183,244,625
2023$180,648,015
2024$172,956,424

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 30 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.